To enquire about sponsorship opportunities for the conference, please contact:
Nick McCudden
E: NicholasMcCudden@arena-international.com
T: +61 280 978 126
We identify and invite individuals we believe to be the best speakers in the market, if you think you can make a difference to the quality of our events please contact the programme director of the event:
Chloe Roberts
E: chloe.roberts@arena-international.com
T: +44 (0) 207 936 6822
CEO,Profusa, Inc
Biography: From his early exposure as an undergraduate research fellow at the lab of Leroy Hood at Caltech where the automated DNA sequencer was developed, to bringing cutting edge life-sciences tools to the market at Life Technologies Corp. (acquired by Thermo Fisher Scientific, Inc.), Ben has both seen and led scientific and technological transformations that have changed our world for the better. Professional experiences: Life Technology, McKinsey and Company, Los Angeles Dodgers Education: Ph.D., The Johns Hopkins University
Session Details: CASE STUDY 04-03-2020, 2:45 pm View In Agenda
Senior Vice President of Operations,Zosano
Biography: Hayley Lewis serves as the Senior Vice President of Operations, where she oversees the functional areas of Nonclinical, R&D, Analytical Development and QC, Operations and Engineering, Manufacturing, and Regulatory Affairs, and continues to be responsible for overseeing all regulatory interactions with the FDA and other government agencies. Hayley joined the company as the Vice President of Regulatory Affairs and Quality in October 2015. Prior to joining Zosano, Hayley spent over 11 years in Regulatory Affairs at Depomed, Inc., a specialty pharmaceutical company, where she was involved in the approval of 3 commercial products. Over the course of her career, she has enabled 9 investigational products to be studied in humans, 6 of which have advanced to completion of Phase 3 trials. Hayley’s pharmaceutical development experience, spanning over 20 years, covers solid oral dosage forms, and combination products such as systemic and local inhalation products, a single entity combination injectable, and transdermal systems. Ms. Lewis received a B.S. in Pharmaceutical Sciences from the University of Greenwich in England, and has attained several management diplomas from Kellogg School of Management, as well as Stanford’s Graduate School of Business.
Session Details: Medical Device Chair: Jennifer Lee, Senior Director, Head of Oncology Clinical Operations, Radius Health 04-03-2020, 9:00 am View In Agenda
Senior Vice President,BAROnova
Biography: Dr. Cunningham is a veteran clinical executive in medical device industry. She currently serves as Senior Vice President of Clinical & Regulatory Affairs at BAROnova, a medical device company developing innovative solutions for the treatment of obesity. Over the past decade, she has been in clinical and regulatory leadership positions overseeing various stages of clinical programs, ranging from FIM to pivotal to post-market phases. She has a unique perspective in leading clinical programs in a dynamic startup environment.
Session Details: View In Agenda
Co-Founder & CEO,Zenflow
Biography: Nick is a serial entrepreneur with broad experience in medical devices and digital health. He has nearly fifteen years of experience as a healthcare entrepreneur, engineer, and leader. He is currently Co-Founder & CEO of Zenflow, a clinical-stage company developing a novel office-based therapy for urinary obstruction related to benign prostatic hyperplasia (BPH). Zenflow has raised over $35 million in funding and treated over 50 patients successfully to date. Zenflow originated in the Stanford Biodesign fellowship, where Nick and co-founder Shreya Mehta spent one year as fellows. Prior to Biodesign, Nick co-founded Avail MedSystems (f.k.a. Nurep), a company aiming to transform surgical support. Nurep allows medical device representatives to support operating room cases remotely via a mobile device. In this role, Nick led the technical development effort to bring the company's product to market and also played key roles in strategy, sales, and fundraising. Nick also spent four years as a Research Engineer at EBR Systems developing a leadless cardiac pacing system. In this role, he designed and implemented several key algorithms critical to the functionality of the device. Before EBR, he worked in R&D engineering for Kensey Nash Corporation and performed clinical research in Cardiothoracic Surgery at Washington University in St. Louis. Nick grew up on the east coast and earned his M.S. and B.S. with Distinction in Management Science & Engineering from Stanford University.
Session Details: Best practices for working with CROS across different global regions 04-03-2020, 11:45 am View In Agenda
Chair of the Board of Directors,Embolx, Inc
Biography:
Norm Gitis has earned Ph.D. in Engineering, has authored over 150 scientific papers, three books and over two dozen patents, chaired and organized over three dozen international scientific conferences.
Norm founded and ran two profitable test-instrumentation companies, Center for Tribology, Inc. in Mountain View (1994-2000) and CETR in Campbell (2000-2011). He was twice named by the Business Journal the CEO of Top 20 Fastest Growing Private Companies in Northern California.
He is a managing partner of Lymo Ventures, Board chair of two medtech startups, Board observer of two other medtech startups. His investment portfolio includes two dozen med-tech and a half-dozen biotech startup companies. Norm serves on screening committees of Life Science Angels and Band of Angels, both in Silicon Valley.
Session Details: View In Agenda
Head of Global Clinical Affairs,Natus Medical Incorporated
Biography: Ms. Verma is Director of Global Clinical Affairs with Natus Medical, founder and President of ClinVitals and Advisory member with Wai Technologies bringing extensive expertise in Medical Device clinical research and product development. A recognized health care and life science leader with more than 20 years of mentoring experience, leadership skills, strategic thinking in multi-therapeutic acumen. Ms Verma has served several start-up and public firms encompassing all phases and types of Medical Device clinical research.
Session Details: View In Agenda
CEO,Vitruvian Medical Devices
Biography: Mr. Mahendroo is CEO of Vitruvian Medical Devices, an early stage start-up developing medical devices and therapeutics focused on the wound care market, founded by two UCSF professors and surgeons. He is also an active Lifesciences Angel Investor with 15 investments in companies ranging from advanced medical devices to CAR-T cell therapeutics. He is a founding Board member of Flock Software, Inc., member of the Band of Angels, Sierra Angels & Life Science Angels, and has served on the Board of Investment Groups (Life Science Angels), Private Companies and Non-Profits (The Tech, San Jose, CA). He has been CEO of two VC-backed start- ups & COO of a third one (all achieved liquidity), raised over $50M in VC and strategic funding, and is an active mentor at StartX at Stanford University. He previously worked at Applied Materials, as Chief Marketing Officer and President of the Global Services Business Unit, at Chips and Technologies as Head of Marketing, and at Intel, in Marketing and Operational roles across different product lines. He has extensive experience in marketing technology products in global markets, and in all parts of revenue generation from market exploration and product definition to early sales, scale up, managing the supply chain, manufacturing, distribution and service. Mr. Mahendroo has a Bachelor of Technology degree in Electrical Engineering from the Indian Institute of Technology, Delhi, and an MBA from Harvard Business School. He is a winner of the IIT Delhi Distinguished Alumni award.
Session Details: FIRESIDE CHAT 04-03-2020, 1:45 pm View In Agenda
Assistant Director, Pharmaceuticals & Chemicals Center for Excellence & Expertise US Borders and Customs,
Co-Founder, Clinical Research Innovation Hub,Microsoft
Biography:
Session Details: KEYNOTE- Microsoft Case Study: Delving into the future of clinical research and identifying best practices for accelerating innovation 03-03-2020, 9:30 am View In Agenda
VP, Global Head Statistical Sciences,Abbvie
Biography:
Session Details: PANEL DISCUSSION 03-03-2020, 11:00 am PANEL DISCUSSION 03-03-2020, 1:45 pm Abbvie Case Study: Introducing the Synthetic Control Arm 04-03-2020, 9:00 am View In Agenda
VP Clinical Operations,Ascendis Pharma
Biography: JACQUIE MARDELL has over 35 years of pharmaceutical and biotech industry and education experience. She has a broad background in planning, implementing, monitoring and analyzing clinical development programs, has built clinical operations organizations and led teams in the execution of clinical programs in a wide variety of therapeutic areas in industrialized and emerging countries, and has contributed to several successful product registrations. For 15 years she taught the Good Clinical Practice and elective courses at the UC Santa Cruz certificate program on clinical trial design and management, and she is a regular columnist for ClinicalTrialsArena.com.
Session Details: LIVE DEBATE- Patient recruitment is most successful when taking the grass roots approach compared to investing in social media 03-03-2020, 11:00 am View In Agenda
Lewis, Senior Director R&D Technology,GSK
Biography:
Session Details: Leading the charge to redefine and modernize GSK's technology approach to enable successful trial planning, operational and site engagement 03-03-2020, 2:45 pm View In Agenda
VP Clinical Operations,Dance Biopharm
Biography:
Session Details: PANEL DISCUSSION 03-03-2020, 11:00 am THINK TANK 03-03-2020, 1:45 pm View In Agenda
Founder, the CEO, and chief chemist,Valley Fever Solutions
Biography: David Larwood is a founder, the CEO, and chief chemist for Valley Fever Solutions, running the manufacturing process for a novel antifungal headed for Phase 2a trials in summer 2020. In his role as BD lead, he is responsible for many aspects of the company’s planning and operations. Valley Fever Solutions is a small startup working first on a new and improved treatment for Valley Fever (coccidioidomycosis). Their NikZ will transform the standard of care. Mr. Larwood co-invented his first two commercial molecules before age 30. His PhD research at UC San Francisco established the foundation for PEGylated drugs widely used today, where he co-invented suitable PEGylated lipids to make the very first PEGylated liposomes. As a bench chemist, he was the first to make Iotrolan, a CT contrast agent, now generic. Moving to law, he advised well known companies on patent matters, later moving to Apple Computer. Later, he took a VP role at startup FormFactor, staying in an IP role, then became the first General Counsel for startup Verisity Design, taking them public in 2001, then ultimately through acquisition in 2005. Mr. Larwood is the third of his family to be involved in Valley Fever. His father was a clinician who developed an interest in the disease decades ago when the family moved to Bakersfield, California, a focal area for the disease. His mother started a foundation in about 1998 and raised some $20M for research into vaccines against Valley Fever.
Session Details: PANEL DISCUSSION 03-03-2020, 11:00 am View In Agenda
Co-Founder,Clinical Research Innovation Hub, Microsoft Corporation
Biography: Co-Founder, Clinical Research Innovation Hub, Microsoft Corporation The Clinical Research Innovation Hub (CRIH) is the first industry focused internal startup in Microsoft. Innovation hubs are engines that allow Microsoft to focus on pressing industry problems by combining the speed, agility and autonomy of a startup with resources available to a large enterprise. CRIH analyzes problems deeply through interviews and experiments, then rapidly builds solutions alongside Microsoft customers and partners. Paul is responsible for the strategy of the innovation hub, for establishing a target technology architecture for clinical research, and for building partnerships within and outside of Microsoft that realize the transformation vision. Microsoft and its partners are building solutions that will allow end-to-end digitization of the study, maximize the value of research data and ensure patient needs are met as research modernizes. Paul has been at Microsoft for 8 years. Prior to his current role he worked as Worldwide Director of Industry Strategy for Life Sciences, and as a Director of Enterprise Architecture, focused on developing incubation solutions in the life sciences industry and multiple other industries, including energy production, discrete manufacturing, financial services and education. Before joining Microsoft, Paul was a Senior Enterprise Architect at Weyerhaeuser – a global forest products company. He was responsible for the overall technology architecture of the organization, developed Weyerhaeuser’s virtualization, cloud and security strategies, and defined a target architecture for shared services across multiple lines of business. He is the author or co-author of multiple papers and books on both health and technology issues. He has delivered keynote addresses at multiple conferences in the United States and Europe, including CDISC Interchange, BME Global Pharma Supply Chain Congress, Parexel Horizons, and the Society for Clinical Data Management. He holds a Bachelor of Science (Hons) in Mathematics from King’s College. London.
Session Details: View In Agenda
Co-Founder, ,Clinical Research Innovation Hub, Microsoft Corporation
Biography: Co-Founder, Clinical Research Innovation Hub, Microsoft Corporation The Clinical Research Innovation Hub (CRIH) is the first industry focused internal startup in Microsoft. Innovation hubs are engines that allow Microsoft to focus on pressing industry problems by combining the speed, agility and autonomy of a startup with resources available to a large enterprise. CRIH analyzes problems deeply through interviews and experiments, then rapidly builds solutions alongside Microsoft customers and partners. Ryan is responsible for the operations of the innovation hub, for the management of the portfolio, and for creating the conditions for agile and open innovation. CRIH is enabling Microsoft and its partners to conceptualize, incubate, and ultimately deliver the technology innovations that will drive the adoption of new clinical research paradigms. Ryan has been with Microsoft for 12 years. Prior to his current role he served as a Chief Transformation Officer for the US subsidiary, responsible for designing and executing change management strategies for transforming sales, marketing, and services operations for the $33B business. Before joining Microsoft, Ryan was the CIO for the City of Chicago city council, responsible for implementing IT policies and data security protocols to protect the integrity of sensitive citizen and employee data. He partnered with Microsoft and implementation partners to modernize and transform dozens of legacy systems, enabling greater transparency in government and more citizen-centric applications. Ryan holds a Bachelor of Science in Chemical Engineering from North Carolina State University and a Master of Business Administration from Duke University (The Fuqua School of Business).
Session Details: View In Agenda
Global Solutions Engineer,Furukawa
CEO,KidzSpeak, Inc
Biography: Angie Maurer is a clinical research consultant for almost 14 years and has worked in the industry for almost 20 years working in various clinical operations leadership and management roles overseeing multi-million dollar clinical trials and became an educator and speaker in risk management conducting trainings, seminars, and presentations at small, medium and large industry conferences. More recently, Angie is an executive coach specializing in Emotional Intelligence and also a co-founder, CEO of KidzSpeak, Inc, a 501(c)(3) nonprofit organization that provides a well-rounded public speaking program for children grades K – 12 that integrates Emotional Intelligence skills with public speaking and presentation skills.
Session Details: Discovering the use of emotional intelligence in vendor management 04-03-2020, 1:45 pm View In Agenda
the Vice President of Clinical Development and Medical Affairs,Zosano Pharma
Biography: Donald Kellerman is the Vice President of Clinical Development and Medical Affairs for Zosano Pharma. Dr. Kellerman has more than 30 years of experience working in several areas of the pharmaceutical industry, primarily clinical development. Dr. Kellerman has led registration trials in a number of therapeutic areas, including respiratory, allergy, ophthalmology, cardiovascular, and neurology. From 2008 to 2013, Dr. Kellerman served as Senior Vice President, Clinical Development and Medical Affairs at MAP Pharmaceuticals, Inc., where he led the development of Semprana for migraine. Prior to joining MAP, Dr. Kellerman held management positions at Inspire Pharmaceuticals, Inc. Glaxo Wellcome, plc, Sepracor, Inc., Ciba-GEIGY Corporation, and E.R. Squibb and Sons, Inc. He has served as project leader on multiple development teams including those working on Flovent,® Advair,® and Xopenex®. Dr. Kellerman received his Bachelor of Science and Doctor of Pharmacy from the College of Pharmacy at the University of Minnesota. He has authored major sections of eight NDAs, created labelling strategy for several pharmaceutical products, and has co-authored over 80 publications related to the results of clinical development activities.
Session Details: PANEL DISCUSSION 03-03-2020, 11:00 am Budget Negotiations: Is the process optimized? 03-03-2020, 2:45 pm View In Agenda
Executive Vice President of Operations and Project Management,Amarantus BioScience
Biography: Elise Brownell, PhD. has spent the last 35 years in the bio/pharmaceutical arena where she has played key roles in Discovery, Development and Opportunity Assessment to drive innovation. After completing her doctorate at Yale University, Elise’s career started at SUNY Stony Brook. She continued her interest in comparative molecular biology during her tenure at Frederick Cancer Research Facility and expanded her facility with molecular genetics while in various functions at Bayer Healthcare. Her efforts were widely recognized by promotion to Director, Project Management, where she led global cross-functional teams. Elise also became a member of the founding team of a venture-backed spin out (Aerovance, Inc), where she became head of project management. Dr. Brownell serves in Interim Executive capacities for a number of emergent and highly innovative companies in the Life Science sector, and as a mentor to the entrepreneurs who run them. Elise received her MS, MPhil and PhD from Yale University, and her BS from Allegheny College
Session Details: WORKSHOP: Syncing the investment checklist for both large and small biopharma companies: What are investors looking for? 03-03-2020, 3:30 pm PANEL DISCUSSION:Exploring ways to negotiate and manage study budgets to ensure resources are allocated efficiently 04-03-2020, 2:45 pm View In Agenda
Chair,The Society for Clinical Research Sites (SCRS)
Biography: Archana Sah is an innovative and collaborative clinical development thought leader with 22+ years experience and passion for developing medicines for patients having led and contributed to 15 FDA/EMEA drug approvals in Oncology, Immuno--‐Oncology, Precision Therapeutics, Rare Diseases, Metabolic Diseases and Women's Health. She has held various global positions within Biotech, Big pharma and Oncology startup companies and in the last five years she has taken 10 drugs from research to approvals in the Oncology and Immuno--‐oncology space at Genentech/Roche. She has led highly matrixed, cross--‐functional teams to create value and deliver strategy and execution with several molecules in Phase I--‐III development through approvals. Archana is recognized as a strategic expert on emerging topics ranging from therapeutic landscape/treatment trends expertise to thought leader relationship management. Her passion is to develop high--‐performing teams and create inclusive, empowering and diverse cultures focused on accountability and customer--‐centric mindset. Since January 2018, Ms. Sah also chairs the Society for Clinical Research Sites (SCRS) Oncology Board with a vision to cure cancer through efficiency in process and strength in the relationships between clinical research sites, pharmaceutical companies, and patients. SCRS represents the voice of more than 10,000 Investigators and sites across 47 countries. She provides direction and guidance for the vision, mission and strategic workstreams for the Board. She chairs the Oncology Site Solutions Summit which provides a platform for sites, sponsors, and CROs to come together to learn, communicate and collaborate. Ms. Sah also serves as a member of American Cancer Society Cancer Action Network workstreams on Barriers to Clinical Trial Enrollment Implementation and Clinical Trial Matching. She holds patents, publications, performance awards, and is often an invited speaker at several industry conferences. Ms. Sah received her masters in Pharmaceutical Sciences from University of Cincinnati, College of Pharmacy and a Bachelors in Pharmacy from M. S. University in India
Session Details: FIRESIDE CHAT- Immuno-oncology and personalized cell therapies have proven to be one of the most promising to advance oncology clinical research: But how can we combat the operational challenges? 04-03-2020, 12:15 pm View In Agenda
Neurotrack,VP of Clinical Development
Biography: Jordan Glenn, Neurotrack, VP of Clinical Development Jordan has a diverse background in the digital health space where he has used his expertise in exercise, nutrition, and the psychology of behavior change to focus on disease states such as diabetes and now Alzheimer’s disease. As Neurotrack’s VP of Clinical Development, he helps lead business development/partnerships while also informing the company's research pipeline.
Session Details: PANEL DISCUSSION 03-03-2020, 11:00 am CASE STUDY: Unlocking the potential of digital therapeutics 23-03-2020, 11:15 am View In Agenda
Vice President, Drug Development,Cerecin Inc
Biography: Bruce has over 22 years of experience in leading project teams in the development of innovative medicines, as well as providing strategic guidance, designing preclinical and clinical development programs, and advancing the development of new therapies. Previously, Bruce held leadership roles at Alkahest, Celerion; and Allon Therapeutics. His therapeutic expertise is in CNS indications like Parkinson, Alzheimer and frontotemporal dementias. He started his career on the faculty in the Chemistry Department at Purdue University where his independent research focused on neuronal signal transduction. Bruce earned his doctorate in biochemistry from UCLA and completed a postdoctoral fellowship at the University of California Berkeley.
Session Details: View In Agenda
Associate Director, Site Budgets & Contract Management, Clinical Operations,Ultragenyx Pharmaceutical Inc
Biography: Stephanie Molteni, JD, Associate Director, Site Budgets & Contract Management, Clinical Operations, Ultragenyx Pharmaceutical Inc. Stephanie Molteni is the Associate Director, Site Budgets & Contract Management, Clinical Operations, at Ultragenyx Pharmaceutical Inc. where she oversees a team who manages the global investigator site budgets and contracts. Stephanie is also responsible for the strategic development of the group, focusing on process refinement, key performance indicators and change management. Stephanie has worked with contracts and budgets for more than 20 years, 10 of which at a large medical device company. Prior to entering the biotech industry, Stephanie spent several years in compliance, contracts and operations within the insurance industry.
Session Details: View In Agenda
Senior Director of Business Solutions and Product Manager,OmniComm
Biography: Neil Vivian joined OmniComm in 2009 as Senior Director of Business Solutions and Product Manager. He is responsible for providing technical support to the Business Development group in positioning OmniComm Applications and Services to potential and existing clients. His Product Manager role responsibilities include providing guidance and high level business requirements for new product features based on his industry experience and understanding of new emerging Regulatory Guidance. He has over 40 years’ experience in the software industry, 26 of those focused on Life Sciences built from a solid foundation in the Defense Industry. He has a BSc in Physics and Engineering Science and MSc in Information Technology.
Session Details: Patient Engagement – the future of clinical trials will change 04-03-2020, 11:45 am View In Agenda
Head of Uber Health,Uber
Biography: Dan Trigub leads Uber Health. Before Uber, Dan spent 2.5 years at Lyft as Regional VP of healthcare partnerships. Dan has over ten years of experience in healthcare and founded several companies, including OpenPlacement, a care coordination platform allowing hospital professionals to connect with post-acute care providers for their patients at the moment of discharge. Dan worked in consulting and investment banking in healthcare, and his family owns one of the largest privately-owned homecare business in the Bay Area.
Session Details: UBER CASE STUDY: Removing transportation as a barrier to care 03-03-2020, 12:15 pm View In Agenda
Senior Director , Clinical Compliance, FibroGen,
Biography: Alia is closing in on a 20 year career in the biotech industry where she spent most of her career in Drug Safety. She has worked for large and small biotech companies throughout the Bay Area but has worked at her current company, FibroGen, Inc., since 2010. She took on Drug Safety Compliance in 2013 which brought her over to Clinical Compliance in 2017 where she took on the Trial Master File and other operational compliance functions. Alia is a board certified Family Nurse Practitioner and Registered Nurse and attended UC Berkeley and the University of San Francisco.
Session Details: PANEL DISCUSSION Considering a small company’s perspective on eTMF management for effective running of your clinical trial 04-03-2020, 10:15 am View In Agenda
Head, Supplier Performance Management, Genentech/Roche,
Biography:
Session Details: SPOTLIGHT- Evolving clinical trial outsourcing models and considerations - What really matters? 04-03-2020, 9:00 am View In Agenda
Director, Clinical Procurement and Outsourcing,Ultragenyx Pharmaceutical
Biography: Mark Milberg has over 27 years of management and operational experience in the biopharmaceutical, medical device, and healthcare industries. He currently works as Senior Director, Clinical Outsourcing at Ultragenyx Pharmaceutical Inc., supporting all of the clinical programs in this clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases. He worked at Medtronic previously for 8 years in increasingly responsible positions, including leading the contract function for the entire company. Mark’s career has included work in medical and dental practice management as well. He has both a MSW and a MBA. He was appointed to his local community’s Citizen Finance Oversight/Advisory Committee. Mark has presented at numerous industry conferences and is a well-respected collaborator and influencer in his field.
Session Details: PANEL DISCUSSION:Exploring ways to negotiate and manage study budgets to ensure resources are allocated efficiently 04-03-2020, 2:45 pm View In Agenda
Independent Patient Advocate,
Biography:
Session Details: WORKSHOP: Uncovering specific minorities within patient populations and how to ensure they aren’t being left out of clinical trials 03-03-2020, 2:45 pm View In Agenda
Clinical Program Director, Clinical Operations,Genentech
Biography:
Meghan McKenzie is a Clinical Program Director in Genentech’s Research and Early Development (gRED). Meghan has worked across all phases of drug development for over 20 years. In Clinical operations, she manages complex programs in Neurology and Infectious Disease and is leading gRED’s Patient Centricity team. The gRED Patient Centricity vision is to empower Early Clinical Development to obtain and amplify the patient voice to improve development planning, trial design, and trial execution. This team also focused on Inclusion Research.
She received her Bachelor’s in Economics at UNC- Chapel Hill and her Master’s in Biology: Human Physiology at San Francisco State University. Before joining Genentech in 2005, Meghan held various positions at a CRO, a research site, at NASA in their Human Research Center as well as at nonprofit think tanks in Washington, D.C.
She and her husband (a veterinarian) have two dogs, and they enjoy music and travel with their 19-year old daughter, when they can get her attention.
Session Details: LIVE DEBATE- Patient recruitment is most successful when taking the grass roots approach compared to investing in social media 03-03-2020, 11:00 am PANEL DISCUSSION 03-03-2020, 1:45 pm View In Agenda
Vice President, Information Technology & Digital Health, Blackthorn Therapeutics,
Chief Strategist, Patient Advocates In Research (PAIR),
Biography:
Session Details: LIVE DEBATE- Patient recruitment is most successful when taking the grass roots approach compared to investing in social media 03-03-2020, 11:00 am Divulging the latest in Patient Centricity: Does it exist and what does it mean to different people? 03-03-2020, 4:00 pm View In Agenda
Associate Director, Clinical Development, Nektar Therapeutics,
Biography:
Session Details: PANEL DISCUSSION 03-03-2020, 11:00 am Bridging the gap between technology and healthcare: Disruption in clinical trials 04-03-2020, 11:15 am View In Agenda
Director, Clinical Operations,Cytokinetics
Sr. Director Clinical Operations and Compliance,GRAIL
Biography: Dr Nugent has spent close to 20 years in clinical operations with various medium and large biopharmaceutical companies and has developed multiple quality risk management systems and clinical compliance functions. He is currently a Sr Director/Head of Clinical Operations and Clinical Compliance for GRAIL, Inc.
Session Details: Navigating a case history focusing on the monitoring paradigm 03-03-2020, 3:30 pm View In Agenda
Senior VP Clinical Development and RA, Vaxart,
Sr. Director, Patient Value, Dermira,
Biography:
Session Details: Morning Refreshments & Networking 03-03-2020, 10:30 am Balancing clinical trial perspectives by involving patients in the protocol design phase of your study 03-03-2020, 12:15 pm View In Agenda
Vice President, Clinical Operations and Data Management, Nuvation Bio,
Healthcare IoT Advisor, Global Black Belt Team, Microsoft,
Biography: Sally Ann Frank, Healthcare IoT Advisor | Global Black Belt Team | Americas. As part of Microsoft’s Global Black Belt team, Sally (@sallyafrank) helps healthcare companies use IoT to improve patient outcomes and efficiency. With more than 20 years in the technology industry, she helps providers, payers, medical device, pharmaceutical and life sciences companies use IoT, machine learning, predictive analytics and artificial intelligence to meet the changing demands of the healthcare industry. Focused on business outcomes, Sally has been advising customers about IoT for more than 5 years, starting in the manufacturing sector before focusing on healthcare. She holds an MBA from The George Washington University (Washington, DC), an MS in Systems Management from the University of Southern California and a BS in Marketing and Computer Science from Virginia Tech
Session Details: PANEL DISCUSSION 03-03-2020, 1:45 pm View In Agenda
Director Clinical Operations ,Astex Pharma
Vice President, Musculoskeletal and Metabolic Imaging, BioTel Research,
Biography: Jonathan Riek, PhD serves as the Vice President of Musculoskeletal & Metabolic Imaging for BioTel Research. He has a PhD in Electrical Engineering from the University of Rochester, and his doctoral thesis was on motion and artifact reduction in MRI. He worked on the development of a 3D CT scanner as a postdoctoral researcher, then spent 7 years in the research labs at the Eastman Kodak Company. While at Kodak, Jonathan worked in the areas of motion estimation, frame rate conversion, and video compression. He also served as the liaison between the image science division and the corporate software group. He joined VirtualScopics in 2000 to return to medical imaging and apply his skills interfacing between image science and software. In 2004, he led the development of the system that is still used to run clinical trials and analyze medical images. In his current role, Jonathan has scientific responsibility for all of BioTel Research’s musculoskeletal and metabolic imaging studies, including arthritis, muscle diseases, diabetes, and liver diseases such as NASH and NAFLD. He holds four patents and has published many articles on various topics regarding MRI.
Session Details: PANEL DISCUSSION 03-03-2020, 1:45 pm View In Agenda
CEO, Certum Bio,